{"id":8406,"date":"2021-07-04T10:13:00","date_gmt":"2021-07-04T08:13:00","guid":{"rendered":"https:\/\/www.maiwald.eu\/presseberichte\/royalty-pharma-kuendigt-strategische-finanzierungspartnerschaft-mit-morphosys-in-hoehe-von-2025-milli\/"},"modified":"2022-10-12T13:28:39","modified_gmt":"2022-10-12T11:28:39","slug":"royalty-pharma-announces-2025-billion-strategic-funding-partnership-with-morphosys","status":"publish","type":"presseberichte","link":"https:\/\/www.maiwald.eu\/en\/press-coverage\/royalty-pharma-announces-2025-billion-strategic-funding-partnership-with-morphosys\/","title":{"rendered":"Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With Morphosys"},"content":{"rendered":"\n<ul class=\"wp-block-list\"><li>Royalty Pharma&nbsp;to provide tailored funding solution to enable MorphoSys\u2019 acquisition of Constellation Pharmaceuticals<\/li><li>Investment is anchored by royalties on Janssen\u2019s Tremfya<\/li><li>Partnership also includes royalties on four development-stage therapies, Development Funding Bonds and an investment in MorphoSys common stock<\/li><li>Royalty Pharma to host conference call today,&nbsp;Wednesday, June 2 at 8:45am&nbsp;EDT<\/li><\/ul>\n\n\n\n<p>Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys\u2019 $1.7 billion acquisition of Constellation Pharmaceuticals (Nasdaq: CNST). This partnership is expected to fuel the expansion of the combined company\u2019s capabilities to help enable the development and potential approvals of important cancer treatments.<\/p>\n\n\n\n<p>This funding partnership is anchored by Royalty Pharma\u2019s acquisition of MorphoSys\u2019 rights to receive future royalties on Janssen\u2019s Tremfya (guselkumab). Tremfya is an anti interleukin (IL)-23, approved for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis and is also in clinical development for ulcerative colitis and Crohn\u2019s disease. In 2020, Tremfya generated sales of $1.347 billion.<\/p>\n\n\n\n<p>[&#8230;]<\/p>\n\n\n\n<p>Advisors<\/p>\n\n\n\n<p>Goodwin Procter, Dechert and Maiwald acted as legal advisors to Royalty Pharma. Goldman Sachs Bank Europe SE acted as financial advisor to MorphoSys and Skadden, Arps, Slate, Meagher &amp; Flom LLP acted as its legal advisor. Centerview Partners LLC and PJT Partners acted as financial advisors to Constellation and Wachtell, Lipton, Rosen &amp; Katz acted as its legal advisor.<\/p>\n\n\n\n<p>This text is a press release from Royalty Pharma. The full text version of the article can be found here:&nbsp;<a href=\"https:\/\/www.royaltypharma.com\/news-releases\/news-release-details\/royalty-pharma-announces-2025-billion-strategic-funding\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.royaltypharma.com\/news-releases\/news-release-details\/royalty-pharma-announces-2025-billion-strategic-funding<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-css-opacity\"\/>\n\n\n\n<p>Furthermore, we are pleased about the great response to the closing of the deal in the daily press. Further articles and comments can be found here:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.4investors.de\/nachrichten\/boerse.php?sektion=stock&amp;ID=153376\" target=\"_blank\" rel=\"noreferrer noopener\">4investors.de \u201eMorphosys: Milliardendeals mit Constellation Pharmaceuticals und Royalty Pharma\u201c<\/a>&nbsp;(only available in German)<\/p>\n\n\n\n<p><a href=\"http:\/\/www.aktiencheck.de\/analysen\/Artikel-ROUNDUP_Milliardendeal_Morphosys_uebernimmt_US_Biotechfirma_Aktie_verliert-13189970\" target=\"_blank\" rel=\"noreferrer noopener\">AktienCheck.de \u201eROUNDUP\/Milliardendeal: Morphosys \u00fcbernimmt US-Biotechfirma \u2013 Aktie verliert\u201c<\/a>&nbsp;(only available in German)<\/p>\n\n\n\n<p><a href=\"https:\/\/www.boerse-express.com\/news\/articles\/dgap-adhoc-morphosys-ag-uebernimmt-constellation-pharmaceuticals-und-vereinbart-strategische-partnerschaft-und-finanzierungskooperation-mit-royalty-pharma-deutsch-331559\" target=\"_blank\" rel=\"noreferrer noopener\">Boerse-Express.com<\/a>&nbsp;(only available in German)<\/p>\n\n\n\n<p><a href=\"https:\/\/www.pressebox.de\/inaktiv\/morphosys-ag\/Ad-hoc-MorphoSys-uebernimmt-Constellation-Pharmaceuticals-und-vereinbart-strategische-Partnerschaft-und-Finanzierungskooperation-mit-Royalty-Pharma\/boxid\/1061930\" target=\"_blank\" rel=\"noreferrer noopener\">Pressebox.de<\/a>&nbsp;(only available in German)<\/p>\n\n\n\n<p><a href=\"https:\/\/www.benzinga.com\/pressreleases\/21\/06\/g21385991\/royalty-pharma-announces-2-025-billion-strategic-funding-partnership-with-morphosys\" target=\"_blank\" rel=\"noreferrer noopener\">Benzinga.com<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.bloomberg.com\/press-releases\/2021-06-02\/royalty-pharma-announces-2-025-billion-strategic-funding-partnership-with-morphosys\" target=\"_blank\" rel=\"noreferrer noopener\">Bloomberg.com<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.dgap.de\/dgap\/News\/adhoc\/morphosys-uebernimmt-constellation-pharmaceuticals-und-vereinbart-strategische-partnerschaft-und-finanzierungskooperation-mit-royalty-pharma\/?newsID=1451504\" target=\"_blank\" rel=\"noreferrer noopener\">DGAP.de<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/endpts.com\/breaking-morphosys-swoops-in-with-a-1-7b-deal-to-buy-constellation-adds-2b-plus-in-royalty-pact\/\" target=\"_blank\" rel=\"noreferrer noopener\">EndpointsNews via endpts.com \u201eUPDATED: MorphoSys swoops in with a $1.7B deal to buy Constellation, adds $2B-plus in Royalty pact\u201c<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.evaluate.com\/vantage\/articles\/news\/deals\/morphosys-mortgages-its-future\" target=\"_blank\" rel=\"noreferrer noopener\">Evaluate Vantage by Evaluate.com \u201eMorphosys mortgages its future\u201d<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.globenewswire.com\/news-release\/2021\/06\/02\/2240301\/0\/en\/Royalty-Pharma-Announces-2-025-Billion-Strategic-Funding-Partnership-With-MorphoSys.html\" target=\"_blank\" rel=\"noreferrer noopener\">GlobeNewswire.com<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.law360.com\/mergersacquisitions\/articles\/1390171\/wachtell-skadden-guide-morphosys-1-7b-cancer-co-buy\" target=\"_blank\" rel=\"noreferrer noopener\">Law360.com \u201cWachtell, Skadden Guide MorphoSys&#8217; $1.7B Cancer Co. Buy\u201d<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.marketscreener.com\/amp\/quote\/stock\/ROYALTY-PHARMA-PLC-108435084\/news\/Royalty-Pharma-Announces-2-025-Billion-Strategic-Funding-Partnership-With-MorphoSys-35499127\/\" target=\"_blank\" rel=\"noreferrer noopener\">MarketScreener.com<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/markets.businessinsider.com\/news\/stocks\/royalty-pharma-announces-2-025-billion-strategic-funding-partnership-with-morphosys-1030486769\" target=\"_blank\" rel=\"noreferrer noopener\">MarketsInsider by BusinessInsider.com<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.marketwatch.com\/press-release\/royalty-pharma-announces-2025-billion-strategic-funding-partnership-with-morphosys-2021-06-02-91842749?siteid=bigcharts&amp;dist=bigcharts&amp;tesla=y\" target=\"_blank\" rel=\"noreferrer noopener\">MarketWatch.com<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/stockhouse.com\/news\/press-releases\/2021\/06\/02\/royalty-pharma-announces-2-025-billion-strategic-funding-partnership-with\" target=\"_blank\" rel=\"noreferrer noopener\">StockHouse.com<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.stockwatch.com\/News\/Item\/U-z8247390-U!RPRX-20210602\/U\/RPRX\" target=\"_blank\" rel=\"noreferrer noopener\">StockWatch<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.streetinsider.com\/Corporate+News\/Royalty+Pharma+plc+%28RPRX%29+Announces+%242.025+Billion+Strategic+Funding+from+MorphoSys+AG+%28MOR%29\/18507508.html\" target=\"_blank\" rel=\"noreferrer noopener\">StreetInsider.com<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.wallstreet-online.de\/nachricht\/13993430-royalty-pharma-announces-2-025-billion-strategic-funding-partnership-with-morphosys\" target=\"_blank\" rel=\"noreferrer noopener\">Wallstreet-Online.de<\/a><\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-8406","presseberichte","type-presseberichte","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte\/8406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte"}],"about":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/types\/presseberichte"}],"version-history":[{"count":2,"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte\/8406\/revisions"}],"predecessor-version":[{"id":23278,"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte\/8406\/revisions\/23278"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/media?parent=8406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}